

Vigabatrin

PF-PTD-396

# **Synonyms**

### **Clinical Indication**

Vigabatrin is licensed for use as adjunctive therapy in patients with refractory partial seizures and for the treatment of infantile spasms. Vigabatrin is an antiepileptic drug which acts by irreversibly inhibiting gamma-aminobutyrate aminotransferase, the enzyme responsible for the breakdown of GABA. Vigabatrin blood levels are linearly related to drug dosage and there is little benefit in monitoring blood levels as a guide to dosage required

At present, serum Vigabatrin concentrations are useful in assessing compliance and evaluating risks of toxicity.

Its use has declined following the discovery of visual field defects in 30% of patients treated with the drug.

# Part of Profile / See Also

#### **Request Form**

Combined Pathology manual blood form or ICE request. Note the duration of therapy, daily dose and time of last dose on the form.

## Availability / Frequency of

#### **Analysis**

On request

Weekly

Referred to Epilepsy Centre 8353

### **Turnaround Time**

## **Patient Preparation**

Collect immediately before next dose due (trough level).

### **Sample Requirements**

**Specimen Type** 

Serum

Volume

1 mL

Container



Yellow (SST) tube.



Paediatric Yellow top (SST) tube

### **Reference Range & Units**

2-36 mg/L

**Interferences** 

**Interpretation & Clinical** 

**Decision Value (if applicable)** 

References

**Test code** 

**Lab Handling** 

